RPS6KB2 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, in serial transplantation experiments, CML-KLS+ cells isolated from cefadroxil-treated CML-affected mice completely lost their ability to drive BCR-ABL1+ disease in new recipients, allowing the animals to survive for over 90 days (Fig. 6f).